LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers.
Schmid, P Muthukumar, D Lester, J Khan, S Adams, J Illsley, M Macgregor, C Owadally, W Sarker, S-J
Schmid, P
Muthukumar, D
Lester, J
Khan, S
Adams, J
Illsley, M
Macgregor, C
Owadally, W
Sarker, S-J
Citations
Altmetric:
Abstract
Description
Date
2017-09
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. 2017, 28(suppl_5): Ann Oncol